Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Trial ID or NCT#

NCT00841204

Status

not recruiting iconNOT RECRUITING

Purpose

This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.

Official Title

Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Show Less

Investigator(s)

Susan M. Swetter, MD
Susan M. Swetter, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Melanoma specialist
Professor of Dermatology

Contact us to find out if this trial is right for you.

Contact

Cancer Clinical Trials Office
(650) 498-7061

View on ClinicalTrials.gov